NCT02265666View on ClinicalTrials.gov

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

November 30, 2001

Conditions
Healthy
Interventions
DRUG

BIIL 284 BS Tablet FF

DRUG

BIIL 284 BS tablet C

OTHER

standard breakfast

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY